Vandetanib (CAPRELSA) is an oral medication used primarily for the treatment of medullary thyroid cancer (MTC). It acts by inhibiting key receptor tyrosine kinases involved in tumor growth and metastasis, offering a treatment option for patients with advanced and metastatic forms of this cancer. The drug is taken once daily and is available in tablet form with 100 mg and 300 mg strengths. It requires careful dose adjustments for those with renal impairment and may cause severe cardiac or dermatologic side effects  .

This manual summarizes the essential clinical information based on the drug's official prescribing information. Please consult healthcare providers for personalized medical advice.